Full Member
Dr Reem Ali
Membership since:
2026
About me
My work is focused on identifying new targets for precision medicine in breast and ovarian cancerspreviously we identified the base repair enzyme XRCC1 as a synthetic lethality interacting partner with PARP1 enzyme. Breast and ovarian tumours having low XRCC1 expression are very sensitive to PARP inhibitor drugs. PARP inhibitors have gained rapid FDA approval due to promising response in breast and ovarian tumors. Our work aims to expand the benefit of PARP inhibitors to other cancer patients by finding new DNA repair liabilities in cancer cells.